Latest Conference Coverage

Findings from the US-based study align with results from a phase 1b/2 study completed in China of CT041 in patients with gastric and gastroesophageal junction adenocarcinoma.

The assistant professor of medicine at University of Pennsylvania Hospital stressed the importance of tumor sequencing.

The phase 1, open-label, single-arm study demonstrated favorable safety and robust efficacy for the autologous GPRC5D-directed CAR-T cell therapy.

Data were presented at ASCO 2021 and EHA 2021 for the initial 19 patients. Now, investigators are painting a fuller picture with an additional 9.

The BASECAMP-1 study is currently enrolling participants to explore the feasibility of manufacturing a novel CAR T-cell therapy with a target antigen activator and a HLA LOH-based blocker.

Higher-dose lymphodepleting regimens led to higher toxicity but high response rates.

Cohort A of the CARTITUDE-2 study is evaluating cilta-cel safety and efficacy in patients with multiple myeloma who received 1 to 3 prior lines of therapy.

“Therapy was found to be safe and tolerable. This initial data formed the basis for further exploration that is currently ongoing in the IGNYTE-ESO study,” investigator Sandra P. D’Angelo, MD, tells CGTL.

High response rates were seen in patients that would not meet ZUMA-2 eligibility criteria.

A recent meta-analysis reviewed data across 146 patients in 9 clinical trials.

Relma-cel was previously approved in China in September 2021 for the treatment of B-cell non-Hodgkin lymphoma.

A phase 1 trial evaluated the combination in patients regardless of PD-L1 status and no differences were seen between those negative or positive.

The cofounder, president, and chief executive officer of Forge Biologics discussed the company’s approach to gene therapy manufacturing.

The renowned professor from University of California Los Angeles reflected on receiving the Outstanding Achievement Award from the ASGCT.

Treated patients had significant improvements in fatigue and lymphoma symptoms.

RP-L301 also improved hemolysis and eliminated the need for red blood cell transfusions for up to 1year after therapy.

The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.

The vice president of neuroscience at Sangamo Therapeutics discussed identifying novel capsids with improved neuronal transduction to the CNS.

The chief scientific officer of Sangamo Therapeutics discussed the first-in-human STEADFAST trial.

All study participants met criteria to remain off enzyme replacement therapy through 104 weeks after treatment.

The director of the Liver Tumor Program at Texas Children’s Hospital discussed a phase 1 study of CAR NK T-cells in neuroblastoma.

The cell therapy was tolerated although there was a SUSAR of GGT elevations.

The senior investigator from NINDS discussed findings investigating serious AEs across different trials.

The clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.

In an interview with CGTLive, study primary investigator Donald Kohn, MD, discussed the safety and efficacy observed in the phase 2 trial.

Review top news and interview highlights from the week ending May 20, 2022.

The director of the leukodystrophy service at Mass Gen discussed progress dosing in the phase 1/2 trial.

Motor and pulmonary function have stabilized or improved in participants treated with SGT-001.